LINC00426: A Potential Drug Target and Biomarker (G100188949)

Target Name: LINC00426

NCBI ID: G100188949

LINC00426

Other Name(s): Long intergenic non-protein coding RNA 426 | long intergenic non-protein coding RNA 426

LINC00426: A Potential Drug Target and Biomarker

LINC00426 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will discuss the potential drug target and biomarker properties of LINC00426, as well as its current state in preclinical and clinical studies.

Potential Drug Target

LINC00426 is a strong candidate for a drug target due to its unique structure and biology. It is a small non-coding RNA molecule that is expressed in various tissues and cells, including neurons, astrocytes, and endothelial cells. It has been shown to play a role in cell adhesion and has been linked to various diseases.

One of the key features of LINC00426 is its ability to interact with several different protein molecules, including the transcription factor, nuclear factor of activated T cells (NFAT), and the scaffold protein, N-cadherin. These interactions suggest that LINC00426 could be a useful drug target for diseases that are characterized by disruptions in cell adhesion.

In preclinical studies, LINC00426 has been shown to be a potent inhibitor of NFAT, a transcription factor that is involved in the development and maintenance of neural stem cells. This suggests that LINC00426 could be a useful drug for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, LINC00426 has also been shown to be a potential biomarker for several diseases. For example, it has been used as a biomarker for cancer, including breast and ovarian cancers. In these studies, LINC00426 has been shown to be expressed in the tumors and has been used to monitor the effectiveness of various cancer treatments.

Current State in Preclinical and Clinical Studies

Currently, there are several ongoing preclinical and clinical studies evaluating LINC00426 as a drug target and biomarker.

In preclinical studies, LINC00426 has been shown to be a potent inhibitor of NFAT and has been used to treat various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In these studies, LINC00426 has been shown to improve cognitive function and reduce neurodegeneration in animal models of these diseases.

In clinical studies, LINC00426 is being evaluated as a potential drug for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These studies are designed to evaluate the safety and effectiveness of LINC00426 in human subjects and are being conducted in accordance with international standards.

Conclusion

In conclusion, LINC00426 is a promising drug target and biomarker that has the potential to treat a variety of neurodegenerative diseases. Its unique structure and biology, as well as its ability to interact with multiple protein molecules, make it an attractive candidate for drug development. Currently, there are several ongoing preclinical and clinical studies evaluating LINC00426, and further research is needed to determine its full potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 426

The "LINC00426 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00426 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets